
What to read to understand Xi Jinping
(The original article was published in September 2022) Few world leaders are as shrouded in mystery as Xi Jinping. That is no accident. Mr Xi, plausibly the most powerful man in the world, rarely gives interviews or makes public statements. Those closest to him are sworn to secrecy. China's censors vigilantly scrub from the Chinese internet any information about him that deviates from the state's propaganda. While there are official accounts of his thinking, and of his time as a provincial official, plenty of questions remain unanswered. In October he is expected to secure a third term as chief of the Communist Party, cementing his position as the most influential Chinese leader since Mao. For the past nine months The Economist has been charting Mr Xi's rise. You can listen to the fruits of that research in 'The Prince", our new narrative podcast. Here are some of the books that helped us figure out what makes Mr Xi tick.
Son of Yellow Earth. By Xi Jinping. Published in the National New Bibliography Magazine
Mr Xi was born into a life of privilege in Beijing in 1953. His father, Xi Zhongxun, was a party elder and revolutionary hero who had fought alongside Mao in China's civil war. But his comfortable life was torn apart in the years before the Cultural Revolution, as his father was purged and the younger Xi was ostracised at school. His half-sister committed suicide and his own mother denounced him. All this is recalled in 'Son of Yellow Earth", a biographical essay by Mr Xi that was published in a Chinese journal in 2002. At the age of 15, after his father's fall from grace, Mr Xi was sent to work in rural Shaanxi, where he lived in a cave for seven years. He later conceded that had he stayed in Beijing, he 'might not have survived". But his time in the cave was gruelling. 'I had never seen a flea when I lived in the city," he writes, but soon after arriving in the village his 'whole body became swollen from scratching the flea bites". This is Mr Xi's creation myth. Despite starting life with a silver spoon in his mouth, he claims to have first-hand knowledge of the suffering of common people. As he writes in his illuminating essay, 'the knife is sharpened on a grinding stone."
Xi Jinping: Political Career, Governance, and Leadership, 1953-2018. By Alfred Chan. Oxford University Press; 680 pages; $49.95 and £32.99
How did Mr Xi make it from the cave to the top of the Communist Party? The answer, according to Alfred Chan, a professor of political science at Western University in Canada, was a long, hard slog through the provinces. In this meticulous account, Mr Xi is presented as a savvy apparatchik who sticks firmly to the party line. He managed to emerge unscathed from a huge corruption scandal that exploded when he was in charge of Fujian province. In 2007 he was made party secretary of Shanghai, a prestigious post. There he cleaned up another corruption scandal, accelerating his ascent to the Communist Party leadership. Was it cunning politics that helped Mr Xi beat the competition? Mr Chan argues no: he was just in the right place at the right time. In 2008, when Mr Xi was announced as the presumed successor to Hu Jintao as China's leader, the party was in a crisis, not least because of various corruption scandals. Mr Xi seemed like a capable pair of hands.
Red Roulette: An Insider's Story of Wealth, Power, Corruption, and Vengeance in Today's China. By Desmond Shum. Scribner; 320 pages; $18.99. Simon & Schuster, £20
Desmond Shum was a high roller. With his now ex-wife, Whitney Duan, he cultivated ties with some of China's most important politicians. Through insider deals on the stockmarket and valuable property deals, the pair became multi-millionaires (they deny they broke any laws). But when Mr Xi came to power in 2012, vowing to stamp out corruption, their empire came crashing down. In 2017 Ms Duan, who had divorced from Mr Shum earlier, was snatched in Beijing and disappeared into the maw of the government's anti-corruption campaign.
Mr Shum had already left for Britain. He didn't hear from Ms Duan for years—until she called him days before the release of his tell-all book (which we first reviewed here) about his brush with the upper echelons of Chinese power. Don't publish, she told him. She is still in China, closely monitored by the authorities. Luckily for readers interested in Chinese politics, he ignored her entreaties. His gripping book describes some of the manoeuvres that Mr Xi made to defeat his rivals, many of whom were ensnared by the anti-corruption campaign (certain 'red aristocrats" were spared). According to Mr Shum, Mr Xi was always more interested in power than money. Once, over dinner, Mr Shum tried to take the measure of the future leader of China. Mr Xi sat opposite him, impassive, saying nothing. He wasn't interested in what Mr Shum had to offer.
Deadly Quiet City. By Murong Xuecun.The New Press; 320 pages; $27.99
In 2019, while at home in Beijing, Hao Qun received a knock on the door. Police officers carted him off to the station to reprimand him for tweets he had sent years earlier, which included cartoons of Mr Xi. From that moment he was considered to be a 'sensitive person". After he published 'Deadly Quiet City", under the pen name Murong Xuecun, he feared the authorities enough to leave China. His account of the covid-19 lockdown in Wuhan put a black mark against his name.
Mr Hao's book contains harrowing details of the pandemic's early days. He revealed the anger of people in Wuhan: about the initial cover-up of the novel disease and about the silencing of whistleblowers such as Li Wenliang, the doctor who had raised the alarm before dying of the virus himself. Mr Xi has repeatedly asserted that China's supposed victory over the virus is because of his 'zero-covid" policy. He has staked his political legitimacy on the success of that approach. But Mr Hao's penetrating account is a reminder of the anger and frustration that bubble beneath China's lockdowns.
The Avoidable War: The Dangers of a Catastrophic Conflict Between the US and Xi Jinping's China. By Kevin Rudd. PublicAffairs; 432 pages; $32 and £25
Kevin Rudd, Australia's former prime minister, has met Mr Xi several times. Nonetheless, Mr Rudd felt that he should get to know China's leader a bit better. So in 2017 he made the unusual decision to pursue a PhD on 'Xi Jinping Thought", Mr Xi's official worldview, at the University of Oxford. This book is the product of that academic journey. It is also a plea for dialogue as policymakers in Beijing and Washington move farther apart. Mr Rudd notes that while Mr Xi's musings can feel like ideological gobbledegook, it is possible to piece together a coherent worldview. Mr Xi sees politics as a zero-sum game, having as a child felt the cost of his father losing power. On the international stage, he has no interest in backing down. Instead he talks of the international system experiencing 'great changes unseen in a century".
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
an hour ago
- Mint
Despite trade war, US drug companies turn to China for key cancer treatments
The drug industry has spent months going along with the Trump administration's efforts to move manufacturing and investment into the U.S., and to disentangle the U.S. and Chinese economies. A long list of big pharmaceutical firms have committed tens of billions of dollars to factories and research facilities in the U.S. In the past few months, though, U.S. pharma companies have simultaneously supercharged their interest in China-based biotechs, announcing what are likely to be the biggest deals ever for the rights to experimental medicines invented by Chinese companies. So far, the Trump administration has been silent on the deals, which are worth around $25 billion in upfront and potential milestone payments and seem to fly in the face of White House policy. The deals could one day result in new options for sick patients, but they also pose a major risk to U.S. biotech firms. The domestic drug pipeline relies on capital from Big Pharma, and now those funds may be going to start-ups in Shanghai, rather than Cambridge, Mass. The recent deals follow a successful trial result last year by U.S. biotech Summit Therapeutics of a new immunotherapy cancer drug it licensed from Chinese firm Akeso. In the trial, the drug outperformed Merck's top-selling Keytruda, raising hopes that it could prove a major advancement in cancer treatment. Since then, Big Pharma companies have rushed to get their own drugs to compete with Summit's product. There was one deal in November, when Merck licensed an experimental drug from a Chinese drugmaker for around $500 million up front and another $2.7 billion in potential milestone payments. The biggest deals have come in just the past two weeks. In mid May, Pfizer said it would pay the Chinese biotech 3SBio $1.3 billion up front for its own competitor to the Summit drug, plus billions more in potential milestone payments. Pfizer is also making a $100 million equity investment in 3SBio. This past week, Bristol Myers Squibb said it would pay $3.5 billion over the next three years, plus billions more in potential milestone payments, for half the rights to a similar drug developed by a Chinese company called Biotheus, which German biotech BioNTech acquired a few months ago. These numbers would be big for any biotech licensing deal—the drugs remain far from approval. For Chinese-developed drugs, the payment sizes are unprecedented. 'These are pretty sophisticated companies allocating major capital here," says Craig Garthwaite, a professor and director of the program on healthcare at Northwestern University's Kellogg School of Management, of the latest deals. 'It's demonstrating the validity of the science." It's all happening while Big Pharma is doing its best to show the Trump administration that it can adapt to the president's agenda, as the industry seeks to head off threatened tariffs and drug price limits. Eli Lilly, Johnson & Johnson, Bristol Myers, and others have all announced tens of billions of dollars in planned U.S. investments in manufacturing and research facilities this year. The White House didn't respond to a request for comment. Washington has been increasingly anxious about the rapid development of China's biotech ecosystem. The Biosecure Act, which hasn't passed Congress, targets complex drug manufacturing in China, while a recent report commissioned by Congress called on the U.S. to take 'swift action" to compete with the Chinese biotech sector. Amid those stalled efforts, the pace of Chinese biotech innovation is picking up. Until recently, the U.S. drug industry had largely seen Chinese biotechs as a source for cheaper 'me too" assets, which echo but don't duplicate existing medicines. Now, with the latest cancer drug deals, Chinese companies are innovating a new class of drugs that every Big Pharma firm seems to think it needs to get in on. The Summit drug that got investors, analysts, and companies excited last year is known as a PD-1/VEGF bispecific antibody, which combines two proven cancer-fighting tools. Daina Graybosch, an analyst at Leerink Partners, says that companies in the U.S. and Europe have been experimenting with similar combinations, but never tested them in humans. That's because early-stage human tests are cheaper and easier to run in China than the U.S. All but the largest U.S. biotechs generally develop just one or two experimental medicines at a time, while Chinese biotechs of a similar size 'could have a dozen" different drugs in trials, according to Cantor Fitzgerald analyst Li Watsek. The combination cancer drugs ultimately weren't exciting enough for the U.S. biotechs to prioritize. But Chinese companies moved forward with different variations. When Summit and its Chinese partner got promising results on an antibody that combined PD-1 and VEGF, there were multiple other Chinese biotechs with their own PD-1/VEGF combinations ready to of this is great news for the U.S. biotech sector, which has been battered in recent years by declining share prices, cash shortfalls, and other challenges. Over the past 12 months, the SPDR S&P Biotech exchange-traded fund is down 11.5%, versus a gain of 11.7% for the S&P 500. Watsek says that part of the problem for investors is that it's hard to know what Chinese biotechs are actually working on. 'Right now it's a little bit of a black box, because a lot of these Chinese companies, they may have assets, but it's impossible to track," she says. 'There could be a dozen molecules that are in development that you may not have even heard of." Over the long term, the worries get potentially more complex. 'At some point, it's going to get terminal velocity, and we're going to have a very dangerous competitor next to us," says Joseph Grogan, a senior policy official during the first Trump administration who is now a nonresident senior scholar at the USC Schaeffer Institute. 'If the Chinese establish the flywheel of the ecosystem that we built—of private-sector companies, research and development, government support, and strong but prudent regulatory foundation—then we're cooked." Write to Josh Nathan-Kazis at


Time of India
2 hours ago
- Time of India
The world's auto supply chain is in the hands of a few Chinese bureaucrats
BEIJING: In a hulking grey building just east of Tiananmen square in Beijing, a small team in China's Ministry of Commerce is deciding the fate of the global auto industry , one rare earth magnet export permit at a time. China holds a near-monopoly on rare earth magnets - a crucial component in electric vehicle motors - and it added them to an export control list in April as part of its trade war with the United States, forcing all exporters to apply to Beijing for licenses. It falls to the Bureau of Industrial Security and Import and Export Control - which is part of China's Ministry of Commerce - to review export permits for the rare earth magnets, which are vital for car motors, wind turbines and even U.S. F-35 fighter jets. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 무릎이 붓고 아프신 분들만 읽으세요. 큰딸민지 더 알아보기 Undo While dozens of licences have been issued since late April, executives, lobbyists and diplomats say they are only a small fraction of the applications that have flooded in from automakers, semiconductor companies and aerospace firms around the world since the tougher export controls were introduced. Washington says delays in issuing export licences show China is reneging on commitments made during trade talks in Geneva last month and it has retaliated with export curbs on plane engine parts and other equipment. Live Events U.S. President Donald Trump and Chinese President Xi Jinping held talks by phone on Thursday as the escalating dispute over China's rare earth stranglehold threatened to derail the fragile trade truce agreed between the two superpowers. When the new rare earth magnet measures came in, the export control bureau had a total of just 30 staff, though this has since been doubled to around 60, according to two sources who were briefed on a meeting between the ministry and Chinese and European semiconductor firms last week. "We appreciate that MOFCOM has increased its resources to address demand and they're working hard and long hours on these issues," said Adam Dunnett, Secretary General of the European Chamber of Commerce in China, referring to the ministry. "But the reality is this is having a huge impact on a wide variety of sectors. It's something that could have been better planned and rolled out," he said. According to personnel records posted to the Ministry of Commerce's website in June 2024, there are only three senior officials within the bureau who can approve the export permits. The ministry's website lists the export licence bureau's office hours as: Weekdays, 8:30-11:30 a.m., 14:00-17:00 p.m. Reuters was unable to determine current staffing levels or whether more officials are now able to approve applications. The Ministry of Commerce did not respond to questions from Reuters on this subject. Chokepoint The global alarm over shortages underscores the enormous leverage China has acquired through its near-monopoly on rare earth production. It also reveals a complex bureaucratic process that has gone from checkpoint to chokepoint. "The process for our suppliers to apply for export licences for various rare earths ... since April, is complex and time-consuming, partly due to the need to collect and provide a lot of information," a spokesperson for Bosch, the German engineering and technology multinational, said last month. A Chinese-language guide to the process published by the Ministry in late March runs to almost 14,000 Mandarin characters. European auto suppliers alone have filed hundreds of requests since early April, with only about a quarter granted. These applications can range from dozens to hundreds of pages, according to sources who have either filed requests or been briefed about them. Public Ministry of Commerce guidelines require information including technical product descriptions, signed contracts. Descriptions of production facilities and photos of products are also encouraged. China's stated aim is to ensure dual-use items don't end up in military equipment, but officials are often overly cautious even though many applications clearly state commercial use, Dunnett said. "Another concern we have heard from some companies is that they are being asked for sensitive and excessive information that is part of their intellectual property which has led to delays in their applications," Dunnett added. While applications are meant to be processed in 45 working days, the ministry says applications related to national security will take longer, without defining how long. Strategic excuse Cory Combs, head of critical mineral and supply chain research at Trivium China, a policy research group, said it was not clear whether the delays were due to bureaucratic inertia or intentional weaponisation. "We do expect these applications to U.S. end-users to be reviewed on par with other countries and approved whenever they're not for military use," he said. "The issue here is that, is it quick enough for the Trump administration to believe that Beijing has not reneged on the Geneva agreement?" Some U.S. industry figures believe that the bureaucratic backlog is a "strategic excuse". "China can staff up as fast as they want, if they wanted to," said a source from the U.S. rare earths industry who declined to be named for sensitivity reasons. In public, Chinese officials have said the export controls apply to all countries, the implication being that they do not count as a U.S.-specific countermeasure under the Geneva agreement. Foreign ministry spokesperson Lin Jian said on May 30 that the rare earth export controls are "non-discriminatory and not targeted at any specific country". During the Geneva talks, however, China privately admitted that the rare earth export controls qualified as non-tariff countermeasures, according to a source briefed on the talks. Rare earths remain a core part of ongoing U.S.-China discussions, the person said. China's foreign ministry did not immediately respond to a request for clarification. Chinese scholars openly admit that the rare earth export controls are retaliation for U.S. chip curbs. "It's a short-term form of leverage which doesn't hurt China, as the rare earths in question have relatively low monetary value," said Zhu Junwei, an international relations scholar at the Grandview Institution, a Chinese think-tank.


The Print
2 hours ago
- The Print
‘Who created the Taliban': Shashi Tharoor hits back at Pakistani delegation
'This (Pakistan) delegation is going around saying we are also victims of terrorism; we have lost more lives to terrorism than India has. We turn around and say- Whose fault is that? As Hillary Clinton famously said 10 years ago. You can't breed vipers in your backyard and expect them to bite only your neighbours…That's why they (Pakistan) are now getting terrorists attacked by the Tehrik-i-Taliban Pakistan, but who created the Taliban from which the Tehrik-i-Taliban broke off? We all know the answer to that, so let Pakistan look inside it and let it do some serious interior reflection before it goes around pleading innocence and deniability and everything else.' Washington DC: Even as Pakistan's delegation, seeking to put its point across after India's action against terror during Op Sindoor, arrived in Washington Wednesday, India's outreach delegation, led by Congress MP Shashi Tharoor criticised Pakistan's outreach effort. 'Bhutto has been calling his delegation a peace delegation, and it is quite ironic that the Pakistani delegation is speaking the language of peace. It's like the Devil quoting from the scriptures. For a country that is trying to create fake heroes by promoting failed generals to field marshal, they don't know what true leaders look like. Pakistan has been surviving on cheap Chinese imports, including military hardware, which spectacularly failed on the battlefield. So perhaps it is hard for them to digest high-quality, high-calibre military hardware as well as strong democratic leadership on the other side of the border,' Surya said. Earlier, under pressure Bilawal Bhutto made an impassioned call for peace at the UN Headquarters in New York and even called for joint intelligence sharing on terrorism. A theory completely rejected by the Indian side. 'I think the US has understood for some time now that India has a very clear position that there will be no talks with a gun pointed at our head… The problem is that we will not deal with people who are pointing a gun at our heads. I mean frankly, if your neighbour unleashes his Rottweilers* to bite your children and in fact to do worse to your children, and then says, let's talk. You think he's going to talk to him until he either unleashes those Rottweilers* or locks them up in a kennel or puts them to sleep. It's as simple as that. You're not going to talk to people who are pointing guns at your temples. It's not going to happen,' said Congress MP Shashi Tharoor. 'India does not seek war. We have never sought war in our civilisation's history… But that doesn't mean that we will remain passive in the face of Adharma. If there is cessation of aggression, you will have peace, but if you attack us not once, but we are ready to do 100 Operation Sindoor,' said BJP MP Tejasvi Surya. India already has the upper hand as the two delegations come face to face in the US. On Wednesday, House Foreign Affairs Chairman Brian Mast endorsed India's action against terror. 'The world was holding its breath, watching what had taken place, both in disgust and also in anticipation of the response. When you are attacked, you have no choice but to respond. The world does not allow anything else, and those responses needed to take place. We have a great friendship and partnership between our nations, and we see nothing but growth and expansion in the future,' he said. Pakistan is clearly on the back foot as India presents a strong case for itself. A sign of that came on Wednesday when Pakistan PM Shehbaz Sharif again urged US President Trump to facilitate talks with India. India's stance is clear: if there are to be talks, they will only be on terrorism emanating from Pakistan and Pakistan's illegal occupation of part of Jammu and Kashmir. This report is auto-generated from the ANI news service. ThePrint holds no responsibility for its content. Also read: Bilawal Bhutto vs Shashi Tharoor. Pakistanis want to know who will do West outreach better